(Adnkronos) - Malattie eosinofile ed evoluzione dell’approccio terapeutico dell’anticorpo monoclonale mepolizumab sono stati al centro del simposio promosso da Gsk, organizzato nel corso della seconda giornata del XXV congresso nazionale della Società italiana di pneumologia (Sip) che si è svolto al MiCo di Milano dal 16 al 18 novembre. Ad offrire la propria esperienza clinica 2 grandi esperti: Francesco Bini, direttore dell’Uoc di Pneumologia dell’Asst-Rhodense di Garbagnate Milanese, sull’Egpa, granulomatosi eosinofila con poliangioite e Nicola Scichilone, direttore della Pneumologia del policlinico P. Giaccone di Palermo, sull’arma grave.
Category
🗞
NewsTranscript
00:00Eosinophile diseases and the evolution of the therapeutic approach of the monoclonal antibody
00:10Mepulizumab have been at the center of the symposium promoted by GSK, organized during the second day of the 25th National Congress of the Italian Society of Pneumology,
00:20entitled Pneumology, the future is now, which took place in Mico di Milano from November 16 to 18.
00:27The clinical trials with the use of Mepulizumab in patients with serious asthma
00:36have confirmed the effectiveness of the drug in the clear reduction since the first supply of reacutizations,
00:46on the control of symptoms and on the improvement.
00:49The real-life studies have confirmed not only the improvement since the initial phases,
01:02but also the maintenance of this gain in terms of quality of life and the clinical and biological parameters that have been analyzed.
01:12The future is to evaluate in a longer period of time the maintenance of the clinical remission.
01:21The data are encouraging in this sense, but also the clinical experience that anyone who works on the field knows that can keep
01:30and knows that can count on an effective drug like the antithelioquine 5 and Mepulizumab.
01:36Granulomatosis eosinophila with polyangiitis and GPA is a rare disease characterized by inflammation of the blood vessels
01:43of small and medium sizes, potentially risky for patients with serious asthma.
01:48The coincidence is between 2 and 7 cases per million inhabitants, while the prevalence is between 10 and 13 cases per million inhabitants.
01:56Thanks to Mepulizumab it is possible to reduce the reacutizations of the disease.
02:01In the maintenance of the disease and in the treatment of the relapses of the disease,
02:07since 2017 by the MIRRA study, we have the possibility of using a monoclonal antibody, Mepulizumab,
02:14and it allows to block the interleukin 5, which in turn is the most specific and main growth factor of eosinophils,
02:21which are the key driver cell of the pathogenesis of the vascular disease called GPA.
02:28Mepulizumab allows to reduce the amount of systemic steroids given to the patients,
02:38with consequent benefits on the side effects, which are really very broad,
02:43such as diabetes, the risk of infectious diseases, osteoporosis, hypertension, eye damage.
02:50Mepulizumab also allows to have an increase of the weeks in which the pathology is under control,
02:57that is, the time from the first relapse of the disease.